Hikma launches generic Zortress
Hikma is introducing everolimus tablets, a new generic product used to prevent rejection of organ transplantation in kidney and liver transplantation patients. The product is available in dosage strengths of 0.25mg, 0.50mg and 0.75mg.
Everolimus tablets is the generic of Novartis’ Zortress. Everolimus is indicated for the prophylaxis of organ transplantation in adult patients at low-moderate immunologic risk receiving a kidney transplant; and prophylaxis of organ rejection in liver transplantation.
“We are very pleased to be providing patients and health care providers in the United States with a generic version of this important medicine,” said Brian Hoffmann, Hikma president of generics. “The launch of everolimus tablets expands our diversified portfolio of generic medicines in the United States and, as a paragraph IV product, demonstrates our ability to successfully litigate and bring greater value to our customers and patients in the United States.”
Everolimus tablets, 0.25mg, 0.50mg and 0.75mg, had a market value of approximately $150 million in the 12 months ending January 2020, according to IQVIA.